ArticlePharmacoEconomics - open2018

Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis.

Tzeyu L Michaud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.